Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 4—April 2018
Research

Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010–2016

Charlene M.C. RodriguesComments to Author , Jay Lucidarme, Ray Borrow, Andrew Smith, J. Claire Cameron, E. Richard Moxon, and Martin C.J. Maiden
Author affiliations: University of Oxford, Oxford, UK (C.M.C. Rodrigues, E.R. Moxon, M.C.J. Maiden); Public Health England, Manchester, UK (J. Lucidarme, R. Borrow); Glasgow Royal Infirmary, Glasgow, Scotland, UK (A. Smith); University of Glasgow, Glasgow (A. Smith); Health Protection Scotland, Glasgow (J.C. Cameron)

Main Article

Figure 4

Changes in BAST prevalence before and after Bexsero implementation among invasive meningococcal disease isolates, United Kingdom, 2010–2016. Frequency of BASTs is shown for the period before implementation of Bexsero vaccine, July 2010–August 2015 (dark blue), and after implementation, September 2015–June 2016 (light blue). The most frequently occurring BASTs preimplementation were 2,¶ 221, 219,¶ 220,# 222,¶ 267, 225, 223,# 1576, and 349. The most frequent BASTs postimplementation were 2,¶ 221,

Figure 4. Changes in BAST prevalence before and after Bexsero implementation among invasive meningococcal disease isolates, United Kingdom, 2010–2016. Frequency of BASTs is shown for the period before implementation of Bexsero vaccine, July 2010–August 2015 (dark blue), and after implementation, September 2015–June 2016 (light blue). The most frequently occurring BASTs preimplementation were 2,¶ 221, 219,¶ 220,# 222,¶ 267, 225, 223,# 1576, and 349. The most frequent BASTs postimplementation were 2,¶ 221, 219,¶ 225, 220,# 232,¶ 8,¶ 1576, 228, and 349. *p<0.00001; †p<0.01; ‡p<0.05; §p<0001; ¶BAST contains a potentially cross-reactive match to BAST-1; #BAST contains an exact match to BAST-1. BASTs with significant changes preimplementation and postimplementation were BAST-2 (fHbp 22, NHBA 29, NadA 6, PorA-VR1:5, and PorA-VR2:2), p<0.00001; BAST-221 (25; 7; 0; 5–1; 10–1), p = 0.006; BAST-220 (4; 2; 0; 7–2; 4), p = 0.02; BAST-232 (4; 2; 0; 12–1; 16), p = 0.01; and BAST-8 (22; 29; 121; 5; 2), p = 0.0005. BAST, Bexsero Antigen Sequence Type.

Main Article

Page created: March 19, 2018
Page updated: March 19, 2018
Page reviewed: March 19, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external